All In MedTech

FDA Clearance Tracker · P170002-S026

RHA® Redensity Mepi, RHA®2 Mepi, RHA®3 Mepi, RHA®4 Mepi

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 13, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 13, 2023

Approved

Time to decision

240 days

Received Feb 15, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P170002-S026
Device name
RHA® Redensity Mepi, RHA®2 Mepi, RHA®3 Mepi, RHA®4 Mepi
Applicant
Teoxane S.A.
Applicant location
Geneva
Received
Feb 15, 2023
Decided
Oct 13, 2023
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P170002

Device type

Device class
Class III

Every decision under product code LMH

FDA's approval statement

As written in FDA's record.

Approval of RHA® Redensity Mepi injection into the dermis and superficial dermis of the face, for the correction of moderate to severe dynamic perioral rhytids, in adults aged 22 years or older. Approval of RHA®2 Mepi, RHA@3 Mepi for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older. Approval of RHA@4 Mepi for injection into the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older.

Source documents

Other decisions for Teoxane S.A.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.